In the high-stakes world of advanced therapies, the most critical bottleneck often isn't the science. It's the factory. For patients waiting on a gene therapy for a rare disease or a personalized cell therapy for cancer, the distance between a promising clinical trial and a vial on the shelf is measured in years and constrained by a global network of specialized manufacturing plants, many of them overseas. National Resilience, known simply as Resilience, launched in 2020 with a thesis as straightforward as it is capital-intensive: to build a domestic, technology-forward manufacturing network that could make these complex medicines at scale, and keep the supply chain secure [TechCrunch, 2020-11-23].
The manufacturing wedge
Resilience operates as a contract development and manufacturing organization (CDMO), but its differentiation is rooted in scale and intent. Instead of building single, bespoke facilities, the company rapidly assembled a network through significant capital raises and strategic acquisitions of existing high-end biologics plants from companies like Sanofi and Amgen [Perplexity Sonar Pro Brief]. This allowed it to quickly offer end-to-end manufacturing for the most complex modalities: cell therapies, gene therapies, viral vectors, and mRNA vaccines. Its early work manufacturing mRNA vaccine substance for Moderna's COVID-19 vaccine provided a high-profile proof point for its rapid scaling capabilities [Fierce Pharma].
The company's leadership framed this not just as a business, but as a matter of national health security. The bet was that biopharma companies, and government agencies, would pay a premium for a reliable, North American-based partner to de-risk their most valuable pipelines. This is a capital-intensive model, requiring billions to acquire, retrofit, and equip facilities with advanced technologies like continuous manufacturing and automation. Resilience secured that war chest, raising more than $2 billion in total capital, including equity and debt, to fund its ambitious build-out [Stat News].
The team behind the build
The founding coalition brought together venture capital firepower with decades of operational experience at the highest levels of big pharma. This table outlines the key architects:
| Name | Role | Prior Experience |
|---|---|---|
| Rahul Singhvi | Co-founder, former CEO | Former CEO of Novavax; Operating Partner at Flagship Pioneering [Forbes, 2021] |
| Robert Nelsen | Co-founder | Co-founder and Managing Director of Arch Venture Partners [ARCH Venture Partners, 2026] |
| Patrick Yang | Co-founder, Vice Chairman | Former EVP of Global Manufacturing and Quality at Roche/Genentech [Perplexity Sonar Pro Brief] |
| Drew Oetting | Co-founder | Co-founder and President of venture firm 8VC [8VC] |
This blend was deliberate. Nelsen and Oetting provided the venture capital relationships and initial vision, while Singhvi and Yang brought the deep, practical knowledge of what it takes to develop, scale, and quality-control complex biologics. Singhvi, who cut his teeth in vaccine manufacturing at Merck, provided the initial CEO leadership before transitioning out in 2024 [Forbes, 2021]. The broader executive team was similarly drawn from top roles at Amgen, Sanofi, and Merck, giving potential customers confidence in Resilience's operational rigor [Perplexity Sonar Pro Brief].
A strategic pivot and consolidation
By mid-2025, the ambitious expansion entered a new phase. Resilience announced a strategic restructuring, planning to wind down operations at six facilities across California, Massachusetts, and Florida [BioPharma Dive]. This was accompanied by layoffs affecting hundreds of employees at sites in Florida and North Carolina [Endpoints News]. The moves signaled a shift from a land-grab acquisition strategy to a focus on optimizing its network and doubling down on its most strategic, technologically advanced sites in the Midwest and Ontario.
This consolidation is a natural, if painful, evolution for a capital-heavy startup that scaled rapidly. The initial model of acquiring any available capacity made sense for speed, but not all facilities are equally suited for the high-margin, advanced therapy work Resilience is targeting. The pivot suggests a refinement towards a leaner, more integrated network. It also coincided with a leadership change, as industry veteran William Marth took over as CEO from founder Rahul Singhvi, likely to steer this next chapter of operational maturity [Fierce Pharma].
Navigating a crowded and capable field
The CDMO space is not a green field. Resilience is competing with established, global giants who have their own advanced therapy capabilities. The competitive set is formidable:
- Lonza & Samsung Biologics: Powerhouses in large-scale biologics manufacturing, now heavily invested in cell and gene therapy.
- WuXi Biologics & WuXi AppTec: Chinese leaders offering lower-cost capacity and integrated R&D services.
- Catalent & Thermo Fisher: Large, diversified players with significant fill-finish and development expertise.
Resilience's answer to this competition rests on three pillars. First, its North American footprint is a geopolitical advantage for companies wary of overseas supply chain dependencies. Second, its technology investment in next-generation manufacturing aims to improve efficiency and lower costs over time. Third, its founder-level relationships with top-tier biotech VCs like Arch and 8VC can serve as a powerful business development channel, funneling their portfolio companies to Resilience as a preferred partner.
The patient at the end of the line
Ultimately, the success of Resilience's bet will be measured in patient outcomes. The company is building infrastructure for some of medicine's most promising, yet logistically daunting, treatments. For a child with spinal muscular atrophy, a gene therapy is a one-time, curative intervention. For a patient with relapsed B-cell lymphoma, a CAR-T cell therapy is a last line of defense. These are not commodities; they are personalized, living medicines that require exquisite care in manufacturing.
The standard of care today for many of these advanced therapies involves complex, global logistics. Viral vectors might be produced in one country, cell processing done in another, and final administration at a hospital with a specialized apheresis unit. Delays at any point can be life-altering. Resilience's proposition is to compress and secure that chain within a controlled network. Its recent restructuring, while a setback in sheer footprint, may ultimately strengthen its ability to deliver on that promise for the specific disease states it chooses to prioritize,from oncology and rare genetic disorders to future pandemic-response vaccines.
The next twelve months will be about proving that the consolidated model works. Key milestones will be landing new, flagship partnerships with biotech companies in late-stage clinical trials, demonstrating the cost and speed advantages of its advanced manufacturing tech, and achieving consistent operational excellence across its remaining sites. For the patients waiting, a resilient supply chain isn't an abstract concept. It's the difference between a treatment being a published paper and a tangible hope.
Sources
- [TechCrunch, 2020-11-23] Resilience raises over $800 million to transform pharmaceutical manufacturing in response to COVID-19 | https://techcrunch.com/2020/11/23/resilience-raises-over-800-million-to-transform-pharmaceutical-manufacturing-in-response-to-covid-19/
- [Perplexity Sonar Pro Brief] Company overview and differentiation | Various snippets
- [Fierce Pharma] Resilience manufactures mRNA for Moderna; CEO transition | https://www.fiercepharma.com/manufacturing
- [Stat News] Resilience raises more than $2 billion in total capital | https://www.statnews.com
- [Forbes, 2021-04-15] Rahul Singhvi profile and background at Merck | https://www.forbes.com/sites/amyfeldman/2021/04/15/one-billion-doses-on-day-one-vaccine-company-claims-world-changing-innovation/
- [ARCH Venture Partners, 2026] Robert Nelsen role | https://www.archventure.com
- [8VC] Drew Oetting role | https://8vc.com
- [BioPharma Dive] Resilience to wind down six facilities | https://www.biopharmadive.com/news/national-resilience-manufacturing-operations-wind-down/750246/
- [Endpoints News] Layoffs at Florida and North Carolina plants | https://endpts.com
- [Manufacturing Dive] Leadership change and restructuring details | https://www.manufacturingdive.com